The scientist’s investigation covers issues in Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Immunology and Leukemia. His Internal medicine study combines topics in areas such as Gastroenterology, Surgery and Oncology. His biological study spans a wide range of topics, including CD34, Stem cell, Histocompatibility, Prospective cohort study and Acute leukemia.
His research in Hematopoietic stem cell transplantation intersects with topics in Bone marrow, Minimal residual disease and Antigen. In Immunology, Xiao-Jun Huang works on issues like Granulocyte colony-stimulating factor, which are connected to Immune tolerance. As a part of the same scientific study, Xiao-Jun Huang usually deals with the Leukemia, concentrating on Cancer research and frequently concerns with Metabolite.
His primary areas of study are Internal medicine, Hematopoietic stem cell transplantation, Transplantation, Immunology and Gastroenterology. Xiao-Jun Huang has researched Internal medicine in several fields, including Surgery and Oncology. His Hematopoietic stem cell transplantation study incorporates themes from Acute leukemia, Chemotherapy and Minimal residual disease.
His work deals with themes such as Haematopoiesis, Stem cell, Human leukocyte antigen and Incidence, which intersect with Transplantation. The Gastroenterology study combines topics in areas such as Regimen, Cyclophosphamide, Retrospective cohort study, Platelet Engraftment and Risk factor. His Leukemia research incorporates elements of Myeloid and Cancer research.
Internal medicine, Hematopoietic stem cell transplantation, Transplantation, Cumulative incidence and Gastroenterology are his primary areas of study. His study connects Oncology and Internal medicine. Xiao-Jun Huang works mostly in the field of Hematopoietic stem cell transplantation, limiting it down to topics relating to Acute leukemia and, in certain cases, Donor lymphocyte infusion, as a part of the same area of interest.
Xiao-Jun Huang combines subjects such as Haematopoiesis, Stem cell, Leukemia, Immunology and Human leukocyte antigen with his study of Transplantation. His study in Cumulative incidence is interdisciplinary in nature, drawing from both CEBPA, Hazard ratio, Confidence interval, Clinical endpoint and Cohort. Within one scientific family, Xiao-Jun Huang focuses on topics pertaining to Cyclophosphamide under Gastroenterology, and may sometimes address concerns connected to Regimen.
Xiao-Jun Huang mainly focuses on Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Cumulative incidence and Gastroenterology. Xiao-Jun Huang combines topics linked to Oncology with his work on Internal medicine. His studies in Transplantation integrate themes in fields like Leukemia, Minimal residual disease, Myeloid leukemia and Stem cell.
His Hematopoietic stem cell transplantation research incorporates themes from Donor selection, Prospective cohort study, Human leukocyte antigen and Granulocyte colony-stimulating factor. Xiao-Jun Huang interconnects Myeloid, Cytotoxic T cell, Clinical endpoint and Cohort in the investigation of issues within Cumulative incidence. His research integrates issues of Platelet Engraftment, Framingham Risk Score, Cyclophosphamide and Graft-versus-host disease in his study of Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud;Ellin Berman;Adam Cohen.
Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.
Dao-Pei Lu;Dao-Pei Lu;Lujia Dong;Lujia Dong;Tong Wu;Tong Wu;Xiao-Jun Huang;Xiao-Jun Huang.
Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies
Huang Xj;Liu Dh;Liu Ky;Xu Lp.
Bone Marrow Transplantation (2006)
Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.
Yu Wang;Qi-Fa Liu;Lan-Ping Xu;Kai-Yan Liu.
Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation
Xiao-Jun Huang;Dai-Hong Liu;Kai-Yan Liu;Lan-Ping Xu.
Biology of Blood and Marrow Transplantation (2009)
Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation
Chen-Hua Yan;Dai-Hong Liu;Kai-Yan Liu;Lan-Ping Xu.
Who is the best donor for a related HLA haplotype-mismatched transplant?
Yu Wang;Ying-Jun Chang;Lan-Ping Xu;Kai-Yan Liu.
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
Hong-Hu Zhu;Xiao-Hui Zhang;Ya-Zhen Qin;Dai-Hong Liu.
Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center.
Yu Wang;Dai-Hong Liu;Kai-Yan Liu;Lan-Ping Xu.
CD34+CD38+CD19+ as well as CD34+CD38−CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL
Y Kong;S Yoshida;Y Saito;T Doi.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: